 Connection
Jeffrey Olson to Bevacizumab
This is a "connection" page, showing publications Jeffrey Olson has written about Bevacizumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.221 |
|
|
|
-
Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun; 27(3):219-24.
Score: 0.096
-
Salcedo-Villanueva G, Harasawa M, Velez-Montoya R, Mathias MT, Siringo FS, Olson JL, Oliver SC, Mandava N, Quiroz-Mercado H. Spectral domain optical coherence tomographic analysis of healthy retina in branch retinal vein occlusion and its response to antiangiogenic therapy. Retina. 2015 Apr; 35(4):704-14.
Score: 0.031
-
Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H. Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina. 2013 Sep; 33(8):1487-502.
Score: 0.028
-
Ernst BJ, Garc?a-Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz-Mercado H. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-na?ve proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol. 2012 Nov; 90(7):e573-4.
Score: 0.025
-
Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009 Oct; 18(10):1573-80.
Score: 0.021
-
Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol. 2007 Sep; 27(3):238-40.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|